Westport, CT, April 28, 2015 - In a time when the FDA and state attorneys general are questioning the ingredients and claims of dietary supplements, Americans are looking for assurance that any medicine they use will really work. Infirst Healthcare USA is taking steps, through clinical testing, to ensure that its over-the-counter liquid cold and cough relief medicines, made with FDA-authorized ingredients, are truly effective.
Newly published in the International Journal of Clinical Pharmacy (February 2015), the study - conducted by leading cough researcher, Peter Dicpinigaitis, MD, Director of the Montefiore Cough Center in New York -- is the first to demonstrate the significant ability of diphenhydramine to inhibit cough reflex sensitivity in acute pathological cough (common cold).
"Although diphenhydramine, one of the active ingredients in Dr. Cocoa's Nighttime formula, has been FDA-authorized as a cough suppressant for decades, this new study provides the first clinical evidence that diphenhydramine, as presented in the Dr. Cocoa Nighttime formulation, indeed suppresses the sensitivity of the cough reflex in adults," explains Dr. Dicpinigaitis. "The medication is currently only available on the market in a dosage strength for children."
While these study results are not directly applicable to a child's dosage, they provide important information about the Dr. Cocoa formula, whose active ingredients have long been trusted by parents and authorized by FDA to relieve children's coughs.
"Conducting clinical studies to support the effectiveness of our products is what Infirst Healthcare is all about," says Jamie Barickman, the company's president. "The study by Dr. Dicpinigaitis is extremely significant because it is the first to clearly demonstrate the effectiveness of the Dr. Cocoa formula in treating adult coughs."
For more information, visit http://www.DrCocoa.com, or for the study, visit http://link.springer.com/article/10.1007%2Fs11096-015-0081-8#page-1.
International Journal of Clinical Pharmacy